{
  "drug_name": "Montelukast Sodium",
  "drug_class": "Unknown Class",
  "uses": "1. INDICATIONS AND USAGE Montelukast sodium tablets are a leukotriene receptor antagonist indicated for: \u2022 Prophylaxis and chronic treatment of asthma in patients 2 years of age and older (1.1). \u2022 Acute prevention of exercise-induced bronchoconstriction (EIB) in patients 15 years of age and older (1.2). \u2022 Relief of symptoms of allergic rhinitis (AR): seasonal allergic rhinitis (SAR) in patients 2 years of age and older , and perennial allergic rhinitis (PAR) in patients 2 years of age and older (1.3). 1.1 Asthma Montelukast sodium is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 2 years of age and older. 1.2 Exercise-Induced Bronchoconstriction Montelukast sodium is indicated for prevention of exercise-induced bronchoconstriction (EIB) in patients 15 years of age and older. Pediatric use information for patients ages 6 to 14 years of age for acute prevention of exercise-induced bronchoconstriction (EIB) is approved for Merck...",
  "dosage_info": "2. DOSAGE AND ADMINISTRATION Administration (by indications): \u2022 Asthma (2.1):Once daily in the evening for patients 2 years and older. \u2022 Acute prevention of EIB (2.2): One tablet at least 2 hours before exercise for patients 15 years of age and older. \u2022 Seasonal allergic rhinitis (2.3): Once daily for patients 2 years and older. \u2022 Perennial allergic rhinitis (2.3): Once daily for patients 2 years and older. Dosage (by age): \u2022 15 years and older: one 10-mg tablet. \u2022 2 to 5 years: one 4-mg chewable tablet . \u2022 6 to 14 years: one 5-mg chewable tablet. Patients with both asthma and allergic rhinitis should take only one dose daily in the evening (2.4). 2.1 Asthma Montelukast sodium should be taken once daily in the evening. The following doses are recommended: For adults and adolescents 15 years of age and older: one 10-mg tablet. For pediatric patients 6 to...",
  "common_side_effects": "6. ADVERSE REACTIONS Most common adverse reactions (incidence \u22655% and greater than placebo listed in descending order of frequency): upper respiratory infection, fever, headache, pharyngitis, cough, abdominal pain, diarrhea, otitis media, influenza, rhinorrhea, sinusitis, otitis (6.1). To report SUSPECTED ADVERSE REACTIONS, contact Torrent Pharma Inc. at 1-269-544-2299 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Pediatric use information for patients ages 6 to 14 years of age for acute prevention of exercise-induced bronchoconstriction (EIB) is approved for Merck Sharp & Dohme Corp's montelukast tablet products. However, due to Merck Sharp & Dohme Corp's marketing exclusivity rights, this drug product is not labeled with that pediatric information. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical...",
  "serious_side_effects": "5. WARNINGS AND PRECAUTIONS \u2022 Do not prescribe montelukast sodium to treat an acute asthma attack (5.1). \u2022 Advise patients to have appropriate rescue medication available (5.1). \u2022 Inhaled corticosteroid may be reduced gradually. Do not abruptly substitute montelukast sodium for inhaled or oral corticosteroids (5.2). \u2022 Patients with known aspirin sensitivity should continue to avoid aspirin or non-steroidal anti-inflammatory agents while taking montelukast sodium (5.3). \u2022 Neuropsychiatric events have been reported with montelukast sodium. Instruct patients to be alert for neuropsychiatric events. Evaluate the risks and benefits of continuing treatment with montelukast sodium if such events occur (5.4 and 6.2). \u2022 Systemic eosinophilia, sometimes presenting with clinical features of vasculitis consistent with Churg-Strauss syndrome, has been reported. These events have been sometimes associated with the reduction of oral corticosteroid therapy (5.5 and 6.2). \u2022 Inform patients with phenylketonuria that the 4-mg and 5-mg chewable tablets contain phenylalanine (5.6). 5.1...",
  "contraindications": "4. CONTRAINDICATIONS \u2022 Hypersensitivity to any component of this product (4). \u2022 Hypersensitivity to any component of this product.",
  "warnings": "",
  "source": "OpenFDA API"
}